Blog

Erman Akkus: Adding Tiragolumab to Atezolizumab-Bevacizumab in 1L HCC shows promising results

Erman Akkus/X

Jan 25, 2025, 12:40

Erman Akkus: Adding Tiragolumab to Atezolizumab-Bevacizumab in 1L HCC shows promising results

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post about recent paper by Richard S Finn et al. on X:

“Adding Tiragolumab to Atezo-Beva in 1L of HCC MORPHEUS-Liver:

Anti-TIGIT, phase 1b–2
ORR: 43% vs. 11%
Serious adverse events: 53% vs. 56%
mPFS: 12.3 vs. 4.2 mo
mOS: 28.9 vs. 15.1 mo”

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study

Authors: Prof Richard S Finn, Prof Baek-Yeol Ryoo, Prof Chih-Hung Hsu, Daneng Li, Prof Adam M Burgoyne, Christopher Cotter, Shreya Badhrinarayanan, Yulei Wang, Anqi Yin, Tirupathi Rao Edubilli, Sami Mahrus, Matthew H Secrest, Colby S Shemesh, Nancy Yu, Stephen P Hack, Edward Cha, Prof Ed Gane

Erman Akkus: Adding Tiragolumab to Atezolizumab-Bevacizumab in 1L HCC shows promising results

Anti TIGIT atezolizumab Bevacizumab cancer cancer immunotherapy Erman Akkus HCC MORPHEUS-Liver trial mOS mPFS OncoDaily Oncology serious adverse events The Lancet Oncology Tiragolumab

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC